Cargando…

Response of triploid Atlantic salmon (Salmo salar) to commercial vaccines

While triploid Atlantic salmon represent a practical and affordable solution to the issues associated with sexual maturation in the salmonid aquaculture industry, empirical evidence suggests triploids are more susceptible to disease and vaccine side-effects than diploids. With vaccination now part o...

Descripción completa

Detalles Bibliográficos
Autores principales: Chalmers, Lynn, Migaud, Herve, Adams, Alexandra, Vera, Luisa M., McStay, Elsbeth, North, Ben, Mitchell, Chris, Taylor, John F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academic Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990402/
https://www.ncbi.nlm.nih.gov/pubmed/31877359
http://dx.doi.org/10.1016/j.fsi.2019.12.070
_version_ 1783492493232308224
author Chalmers, Lynn
Migaud, Herve
Adams, Alexandra
Vera, Luisa M.
McStay, Elsbeth
North, Ben
Mitchell, Chris
Taylor, John F.
author_facet Chalmers, Lynn
Migaud, Herve
Adams, Alexandra
Vera, Luisa M.
McStay, Elsbeth
North, Ben
Mitchell, Chris
Taylor, John F.
author_sort Chalmers, Lynn
collection PubMed
description While triploid Atlantic salmon represent a practical and affordable solution to the issues associated with sexual maturation in the salmonid aquaculture industry, empirical evidence suggests triploids are more susceptible to disease and vaccine side-effects than diploids. With vaccination now part of routine husbandry, it is essential their response be studied to confirm their suitability for commercial production. This study tested the response of triploid and diploid Atlantic salmon to vaccination with commercially available vaccines. Triploid and diploid Atlantic salmon siblings were injected with one of three commercial vaccines (or sham-vaccinated) and monitored for performance throughout a commercial production cycle. Sampling at smolt and harvest was undertaken along with individual weight and length assessments through the cycle. Antibody response to Aeromonas salmonicida vaccination was similar in both ploidy, with a positive response in vaccine-injected fish. For both adhesions and melanin, analysis found that higher scores were more likely to occur as the anticipated severity of the vaccine increased. In addition, for adhesion scores at smolt and melanin scores at smolt and harvest, triploids were statistically more likely to exhibit high scores than diploids. Triploids maintained a significantly higher body weight during freshwater and until 11 months post-seawater transfer, with diploids weighing significantly more at harvest. Growth, represented by thermal growth coefficient (TGC), decreased in both ploidy as the severity of adhesions increased, and regression patterns did not differ significantly between ploidy. Vertebral deformity prevalence was consistently higher in triploids (smolt 12.3 ± 4.5%; harvest 34.9 ± 5.9%) than diploids (smolt 0.8 ± 0.5%; harvest 15.9 ± 1.9%), with no significant difference between vaccine groups in each ploidy. This study demonstrates that triploids respond as well to vaccination as diploids and provides further supporting evidence of triploid robustness for commercial aquaculture.
format Online
Article
Text
id pubmed-6990402
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Academic Press
record_format MEDLINE/PubMed
spelling pubmed-69904022020-02-05 Response of triploid Atlantic salmon (Salmo salar) to commercial vaccines Chalmers, Lynn Migaud, Herve Adams, Alexandra Vera, Luisa M. McStay, Elsbeth North, Ben Mitchell, Chris Taylor, John F. Fish Shellfish Immunol Article While triploid Atlantic salmon represent a practical and affordable solution to the issues associated with sexual maturation in the salmonid aquaculture industry, empirical evidence suggests triploids are more susceptible to disease and vaccine side-effects than diploids. With vaccination now part of routine husbandry, it is essential their response be studied to confirm their suitability for commercial production. This study tested the response of triploid and diploid Atlantic salmon to vaccination with commercially available vaccines. Triploid and diploid Atlantic salmon siblings were injected with one of three commercial vaccines (or sham-vaccinated) and monitored for performance throughout a commercial production cycle. Sampling at smolt and harvest was undertaken along with individual weight and length assessments through the cycle. Antibody response to Aeromonas salmonicida vaccination was similar in both ploidy, with a positive response in vaccine-injected fish. For both adhesions and melanin, analysis found that higher scores were more likely to occur as the anticipated severity of the vaccine increased. In addition, for adhesion scores at smolt and melanin scores at smolt and harvest, triploids were statistically more likely to exhibit high scores than diploids. Triploids maintained a significantly higher body weight during freshwater and until 11 months post-seawater transfer, with diploids weighing significantly more at harvest. Growth, represented by thermal growth coefficient (TGC), decreased in both ploidy as the severity of adhesions increased, and regression patterns did not differ significantly between ploidy. Vertebral deformity prevalence was consistently higher in triploids (smolt 12.3 ± 4.5%; harvest 34.9 ± 5.9%) than diploids (smolt 0.8 ± 0.5%; harvest 15.9 ± 1.9%), with no significant difference between vaccine groups in each ploidy. This study demonstrates that triploids respond as well to vaccination as diploids and provides further supporting evidence of triploid robustness for commercial aquaculture. Academic Press 2020-02 /pmc/articles/PMC6990402/ /pubmed/31877359 http://dx.doi.org/10.1016/j.fsi.2019.12.070 Text en © 2019 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chalmers, Lynn
Migaud, Herve
Adams, Alexandra
Vera, Luisa M.
McStay, Elsbeth
North, Ben
Mitchell, Chris
Taylor, John F.
Response of triploid Atlantic salmon (Salmo salar) to commercial vaccines
title Response of triploid Atlantic salmon (Salmo salar) to commercial vaccines
title_full Response of triploid Atlantic salmon (Salmo salar) to commercial vaccines
title_fullStr Response of triploid Atlantic salmon (Salmo salar) to commercial vaccines
title_full_unstemmed Response of triploid Atlantic salmon (Salmo salar) to commercial vaccines
title_short Response of triploid Atlantic salmon (Salmo salar) to commercial vaccines
title_sort response of triploid atlantic salmon (salmo salar) to commercial vaccines
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990402/
https://www.ncbi.nlm.nih.gov/pubmed/31877359
http://dx.doi.org/10.1016/j.fsi.2019.12.070
work_keys_str_mv AT chalmerslynn responseoftriploidatlanticsalmonsalmosalartocommercialvaccines
AT migaudherve responseoftriploidatlanticsalmonsalmosalartocommercialvaccines
AT adamsalexandra responseoftriploidatlanticsalmonsalmosalartocommercialvaccines
AT veraluisam responseoftriploidatlanticsalmonsalmosalartocommercialvaccines
AT mcstayelsbeth responseoftriploidatlanticsalmonsalmosalartocommercialvaccines
AT northben responseoftriploidatlanticsalmonsalmosalartocommercialvaccines
AT mitchellchris responseoftriploidatlanticsalmonsalmosalartocommercialvaccines
AT taylorjohnf responseoftriploidatlanticsalmonsalmosalartocommercialvaccines